miR-34a在复发-缓解型多发性硬化患者血清中表达情况研究

目的检测复发-缓解型多发性硬化患者在急性复发期及缓解期外周血血清miR-34a的表达情况,探讨其作为新的血清标记物的可能性,以及其血清表达情况与疾病活动的关系。方法选取2014年1月至2015年12月在哈尔滨医科大学附属第四医院神经内科就诊的复发-缓解型多发性硬化患者20例为观察组,患者均处于急性复发期且近期未接受任何治疗;患者均接受随访,在缓解期未用药物治疗(免疫调节药物等)。同时,选取年龄、性别与观察组相匹配的20例健康人作为健康组。分别采集两组患者外周静脉血,提取血清总RNA,并对miR-34a进行RT-qPCR检测验证,对观察组急性复发期和缓解期、健康组分别进行多种microRNA的相对定量分析。结果 RT-qPCR检测结果显示,观察组急性复发期与健康组比较,血清中miR-34a的含量明显降低,对照组平均表达量约为观察组急性复发期的1.91倍,差异有统计学意义(P<0.05);miR-34a在观察组缓解期的血清表达与健康组比较,差异无统计学意义(P>0.05)。结论 miR-34a在复发-缓解型多发性硬化患者的急性复发期中表达降低,并可能具有作为复发-缓解型多发性硬化急性复发期诊断的血清生物标志物潜质。     

Emerging role of ultrasonography in rheumatoid arthritis: optimizing diagnosis, measuring disease activity and identifying prognostic factors

Ultrasonography is a sensitive imaging modality that provides valuable information regarding early inflammatory changes that are not detected by clinical examination or X-rays, such as subclinical synovitis and erosions. This information may improve the management of rheumatoid arthritis by providing a more timely and accurate diagnosis, identifying poor prognostic factors, more accurately monitoring response to therapeutic intervention, improving treatment decisions and more accurately assessing remission. Ultrasonography could play a critical role in minimizing disease activity through strict monitoring and aggressive therapeutic adjustment, which has emerged as an approach to improve long-term outcomes for patients with rheumatoid arthritis.     

Toward a more comprehensive assessment of depression remission: the Remission Evaluation and Mood Inventory Tool (REMIT)

Objective

Depression remission continues to be defined in terms of resolution of the Diagnostic and Statistical Manual of Mental Disorders criteria symptoms. However, it may be useful to assess additional symptoms as part of a more complete evaluation of remission. We sought to develop an adjunct self-report measure that can be used with commonly used depression measures when assessing remission.

Methods

Secondary data analysis and expert input were used to develop candidate items that were evaluated cross-sectionally in 1003 primary care clinician-identified depressed patients from two practice-based research networks. Multivariable regression analysis, with self-assessed recovery as the dependent variable, identified five symptoms that contributed significantly beyond the Patient Health Questionnaire (PHQ)-8. Further analysis was performed in selected subsamples.

Results

Emotional control, contentedness, future seeming dark, ability to bounce back and happiness yielded an 11% increase in R² beyond 60% yielded by the PHQ-8. The summed Remission Evaluation and Mood Inventory Tool (REMIT) 5 items have a mean=9.6 (S.D.=4.5), range 0-20 and reliability of 0.86. Subsample analysis showed incremental R² ranging from 9% in men to 15% in African-Americans.

Conclusion

Depression remission is a multidimensional concept that includes important nondepressive symptom dimensions. These important dimensions can be measured using a self-report instrument feasible for routine primary care. Pending longitudinal validation, REMIT5 is a promising tool for depression management.     

Response and remission of subjective well-being in patients suffering from schizophrenia spectrum disorders

Background

Purpose of this study was to assess subjective well-being in schizophrenia inpatients and to find variables predictive for response and remission of subjective well-being.

Method

The subjective well-being under neuroleptic treatment scale (SWN-K) was used in 232 schizophrenia patients within a naturalistic multicenter trial. Early response was defined as a SWN-K total score improvement of 20% and by at least 10 points within the first 2 treatment weeks, response as an improvement in SWN-K total score of at least 20% and by at least 10 points from admission to discharge and remission in subjective well-being as a total score of more or equal to 80 points at discharge. Logistic regression and CART analyses were used to determine valid predictors of subjective well-being outcome.

Results

Twenty-nine percent of the patients were detected to be SWN-K early responders, 40% fulfilled criteria for response in subjective well-being and 66% fulfilled criteria for remission concerning subjective well-being. Among the investigated predictors, SWN-K early improvement and the educational status were significantly associated with SWN-K response. The SWN-K total score at baseline showed a significant negative predictive value for response. Baseline SWN-K total score, PANSS global subscore, and side effects as well as the educational status were found to be significantly predictive for remission.

Conclusions

Depressive symptoms should be radically treated and side effects closely monitored to improve the patient's subjective well-being. The important influence of subjective well-being on overall treatment outcome could be underlined.     

帕利哌酮联合心理干预治疗首发精神分裂症的临床疗效及社会功能研究

目的 评价帕利哌酮缓释片联合心理干预对首发精神分裂症门诊治疗患者的临床疗效及社会功能恢复的疗效.方法 对符合DSM-Ⅳ诊断标准的62例首发精神分裂症患者进行为期12个月的研究.患者随机分为两组,对照组接受帕利哌酮常规治疗;试验组在常规治疗的基础上给予每月1次心理干预.采用阳性与阴性症状量表(PANSS)个人和社会功能量表(PSP)分别在基线和治疗后第1,3,6,9,12月末评定其疗效及社会功能;于治疗9个月后评定临床痊愈等情况.安全性采用Barnes静坐不能量表(BARS)、锥体外系副反应量表(SAS)及不自主运动量表(AIMS)等评定.结果 心理干预联合药物治疗组共27例,单用药物治疗对照组共17例完成试验,脱落率分别为12.9%、45.2%,组间差异具有显著性(P＜0.05).两治疗组治疗后PANSS及PSP总分相对治疗前均有显著改善(P＜0.05),其中心理干预组PANSS减分率＞30%、PSP评分提高≥7、达到临床痊愈标准的患者比例为74.2%、51.6%、67.7%,优于单用药物治疗组的45.2%、38.7%、38.7%(P＜0.05).两治疗组不良事件发生率及类型相似,主要不良反应为锥体外系、心动过速、肠胃道反应、等静坐不能等.结论 帕利哌酮缓释片联合心理干预能提高首发精神分裂症门诊患者的治疗依从性.降低治疗中断率,提高临床痊愈患者比例并促进患者社会功能的康复.     

肺系病缓解期从痰瘀毒论治

肺系病缓解期临床症状轻微或隐匿,但忽视缓解期的治疗,易造成疾病反复发作,最终导致其病理和生理功能难以逆转,严重影响患者的生活质量。应用毒邪理论来研究肺系病缓解期的诊治工作,对于延缓病程进展,减少反复发作次数,改善预后具有积极的意义。     

自体造血干细胞移植对淋巴瘤患者缓解率和生存率的影响

目的:评价自体外周血造血干细胞移植(APBSCT)对提高淋巴瘤患者的缓解率和生存率的作用。方法:回顾性分析53例接受APBSCT淋巴瘤患者临床资料,病理类型以弥漫大B细胞淋巴瘤(DLBCL)为主,占50.94%,中位移植年龄34(12～57)岁,临床分期Ⅲ、Ⅳ期患者占78.8%,年龄矫正的国际预后指数(aaIPI)低危、低中危、中高危、高危患者分别占21.2%、46.7%、15.1%、17.0%。采用统计学分析APBSCT治疗淋巴瘤的疗效及其对生存情况的影响及相关预后影响因素。结果:52例患者成功接受了APBSCT治疗,移植后完全缓解(CR)率65.4%;部分缓解(PR)率19.2%,总反应率(RR)84.6%(CR加PR);其中移植前达CR患者移植后100%CR,PR患者61.2%获CR;1例疾病稳定(SD)患者移植后获CR;17例疾病进展(PD)患者移植后35.3%获CR,17.6%获PR,总反应率为52.9%。中位随访14个月,3年预期总生存(OS)率、无事件生存(EFS)率分别为56%、50%。APBSCT能克服初诊时乳酸脱氢酶(LDH)升高、进展期病变、结外病灶>1、巨块病变、B症状、骨髓浸润所引起的对患者生存期的影响;无法克服体能状态下降、移植前LDH水平升高、进展期病变对生存的影响。结论:APBSCT可提高淋巴瘤患者CR率,改善移植前未达CR患者的OS及EFS,移植前临床特征重新评估对判断预后具有重要意义。     

Clinical importance of serum procalcitonin in ulcerative colitis patients

We have read with interest the recently published article entitled “Clinical significance of serum procalcitonin in patients with ulcerative colitis” by Koido et al. They aimed to investigate the association of procalcitonin with ulcerative colitis (UC) activity. They concluded that elevated procalcitonin levels were significantly correlated with UC activity. We would like to thank the authors for their comprehensive contribution.     

慢性心力衰竭缓解期中医临床论治思路

慢性心力衰竭是一种复杂的临床综合征,根据慢性心衰缓解期的病因病机,总结多年来中医药临床诊治慢性心衰的经验,形成并制定了慢性心衰缓解期的中医药治疗治疗方案,临床应用屡获良效。